{
    "clinical_study": {
        "@rank": "119188", 
        "arm_group": {
            "arm_group_label": "GS-7977+RBV", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive GS-7977+RBV for 24 weeks."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single-arm study of GS-7977 and ribavirin (RBV) in subjects who have\n      had a liver transplant which has become re-infected with hepatitis C. The treatment period\n      is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to\n      72 weeks not including the screening visit."
        }, 
        "brief_title": "Safety of Efficacy of GS-7977 and Ribavirin in Subjects With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Chronic Hepatitis C Virus", 
            "Post Liver Transplant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with evidence of chronic HCV (all genotypes) documented pretransplantation\n\n          -  HCV RNA \u2265 10,000 IU/mL at screening\n\n          -  Absence of organ rejection as documented by post transplant liver biopsy taken no\n             more than 12 months prior to Baseline/Day 1 visit\n\n          -  Liver transplant \u2265 6 months and \u2264 12 years prior to screening\n\n          -  Na\u00efve to all nucleotides/nucleoside treatments for chronic HCV infection\n\n        Exclusion Criteria:\n\n          -  Multi-organ transplant that includes heart or lung recipient\n\n          -  Subjects with de novo or recurrent Hepatocellular Carcinoma(HCC) post transplant\n\n          -  Current use of corticosteroids at any dose > 5mg of prednisone/day (or equivalent\n             dose of corticosteroid)\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) at\n             screening\n\n          -  Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy,\n             hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated\n             cirrhosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "Yes", 
        "id_info": {
            "nct_id": "NCT01687270", 
            "org_study_id": "GS-US-334-0126", 
            "secondary_id": "2012-002417-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-7977+RBV", 
                "description": "GS-7977 400 mg tablet administered orally once daily", 
                "intervention_name": "GS-7977", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sofosbuvir", 
                    "PSI-7977", 
                    "Sovaldi\u00ae"
                ]
            }, 
            {
                "arm_group_label": "GS-7977+RBV", 
                "description": "Ribavirin (RBV) 200-mg tablet(s) administered orally in two divided daily doses. RBV dosing (200-1200) will be determined and adjusted according to participants' hemoglobin value, creatinine clearance, and weight.", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug", 
                "other_name": "Ribasphere\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "state": "Lower Saxony"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grafton", 
                        "country": "New Zealand", 
                        "state": "Auckland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "New Zealand", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Jill M. Denning, MA", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Proportion of participants who discontinue study drug due to an adverse event", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with sustained virologic response (SVR) at 4, 24, and 48 weeks after discontinuation of therapy (SVR2, SVR4, SVR8, and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4, 24, and 48"
            }, 
            {
                "measure": "Proportion of participants who have HCV RNA < LLOQ by visit while on treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Absolute and change from baseline in HCV RNA through Week 8", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 8"
            }, 
            {
                "description": "Virologic failure is defined as virologic breakthrough (participant achieved undetectable HCV RNA levels during treatment but subsequently had detectable HCV RNA while continuing treatment), non-response (HCV RNA \u2265 LLOQ through 24 weeks of treatment), or relapse (participant achieved undetectable HCV RNA levels during treatment maintained undetectable HCV RNA for the duration of treatment or achieved undetectable HCV RNA within 4 weeks of the end of treatment but did not achieve SVR at 4, 24, and 48 weeks posttreatment).", 
                "measure": "Proportion of participants with virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to posttreatment Week 48"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}